Gapping up
In reaction to earnings/guidance:
- DDD +13.4%, TASK +10.9%, TGT +10.9%, SAIL +9.6%, WDAY +7.4%, ADT +7%, EVRI +5.3%, APPF +5.2%, AZO +5.2%, AMRS +4.2%, BIDU +4%, BLDR +3.4%, STRL +3.3%, PRGO +2.8%, KSS +2.5%, NKTR +2.3%, DAR +2.2%, TWNK +1.7%, HGV +1.6%, FRPT +1.5%, AMRN +1.2%, HRL +1%
Other news:
- CTIC +61.6% (announces FDA accelerated approval of VONJO for the treatment of adult patients with myelofibrosis and thrombocytopenia )
- ACI +8.9% (commences review of potential strategic alternatives)
- DRIO +8.9% (enters into strategic multi-year $30 mln agreement with Sanofi (SNY))
- LEGN +7.3% (CARVYKTI BCMA-Directed CAR-T therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma)
- BITF +6.9% (Provides February 2022 Production and Mining Operations Update)
- VALN +3.9% (receives emergency use authorization from bahrain for its inactivated COVID-19 vaccine VLA2001)
- LDOS +3.5% (wins Defense Enclave Services contract)
- EGY +2% (provides update on Etame field reconfiguration and FSO Deployment)
- STLD +1.9% (increases dividend; also authorizes additional share repurchase program of up to $1.25 bln)
- AZN +1.5% (and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006)
- APP +1.4% (to acquire Wurl for $430 mln; also authorizes new $750 mln share repurchase program)
- CVX +1.2% (executing plans to deliver higher returns and lower carbon; Raises share buyback guidance)
Analyst comments:
- TSHA +5% (initiated with an Overweight at Wells Fargo)
- RVMD +3.8% (upgraded to Buy from Hold at Stifel)
- NXTC +3.3% (initiated with a Buy at Ladenburg Thalmann)
- SDGR +1.6% (initiated with a Buy at Citigroup)
- LOGI +1.5% (upgraded to Outperform from Neutral at Wedbush)